CompletedNCT03287869
Brexpiprazole Safety in Adults With Bipolarity: An Open-Label Study
About this title
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
Read the official source — NCT03287869Researchers studied Brexpiprazole, tracking side effects to assess safety and tolerability in people with bipolarity type I.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Brexpiprazole, tracking side effects to assess safety and tolerability in people with bipolarity type I.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 72 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: October 24, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 381
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03287869
- Official title
Show the full official title
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · Rogers, United States · Bellflower, United States
63 more locations
- Cerritos, United States
- Culver City, United States
- Garden Grove, United States
- Glendale, United States
- Long Beach, United States
- Oakland, United States
- Orange, United States
- Panorama City, United States
- Riverside, United States
- San Diego, United States
- Santa Ana, United States
- Torrance, United States
- Yorba Linda, United States
- Coral Gables, United States
- Fort Lauderdale, United States
- Hialeah, United States
- Hollywood, United States
- Largo, United States
- Tampa, United States
- Decatur, United States
- Hoffman Estates, United States
- Winfield, United States
- Shreveport, United States
- Gaithersburg, United States
- Saint Charles, United States
- St Louis, United States
- Berlin, United States
- Hickory, United States
- Raleigh, United States
- Oklahoma City, United States
- Austin, United States
- DeSoto, United States
- Fort Worth, United States
- Garland, United States
- Richardson, United States
- Everett, United States
- Richland, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Novi Iskar, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Rijeka, Croatia
- Zagreb, Croatia
- Gdansk, Poland
- Tuszyn, Poland
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Novi Sad, Serbia
- Dnipro, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Ternopil, Ukraine
- Vinnitsa, Ukraine
Questions about this study
What did researchers investigate?
Researchers studied Brexpiprazole, tracking side effects to assess safety and tolerability in people with bipolarity type I.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexpiprazole.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
